Article
Gastroenterology & Hepatology
Jian Wang, Jiacheng Liu, Yilin Liu, Ruifei Xue, Jie Zhan, Suling Jiang, Li Wang, Xiaomin Yan, Yali Xiong, Juan Xia, Shengxia Yin, Xin Tong, Yuxin Chen, Jie Li, Rui Huang, Chao Wu
Summary: This study found that lean patients with chronic hepatitis B (CHB) and nonalcoholic fatty liver disease (NAFLD) accounted for 25% of the CHB-NAFLD patients. Compared to nonlean patients, lean patients had a lower proportion of metabolic abnormalities and advanced liver fibrosis, but had higher levels of HBsAg, HBV DNA, and HBeAg-positive proportions.
HEPATOLOGY RESEARCH
(2023)
Review
Infectious Diseases
Yuting Diao, Juan Tang, Xuerong Wang, Wei Deng, Jing Tang, Chunfang You
Summary: Chronic hepatitis B often coexists with metabolic syndrome and nonalcoholic fatty liver disease. Both metabolic syndrome and nonalcoholic fatty liver disease are associated with obesity and insulin resistance, which can lead to adverse effects on the liver and other organs. The relationship among chronic hepatitis B, metabolic syndrome, and nonalcoholic fatty liver disease is complex and requires further investigation.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Pharmacology & Pharmacy
Changtian Su, Qin Yang
Summary: This study aimed to investigate the clinical efficacy of Ganshuang granules combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease. The results showed that the combination therapy significantly improved liver function index, reduced liver hardness, and decreased fat attenuation parameters.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Virology
Yanhua Tang, Rong Fan, Zhixian Lan, Qing Xie, Jiping Zhang, Xieer Liang, Hao Wang, Deming Tan, Jun Cheng, Shijun Chen, Qin Ning, Xuefan Bai, Min Xu, Xinyue Chen, Junqi Niu, Junping Shi, Hong Ren, Zhiliang Gao, Maorong Wang, Xiaoguang Dou, Jinlin Hou, Jian Sun
Summary: This study found that the percentage of chronic hepatitis B (CHB) patients with concurrent nonalcoholic fatty liver disease (NAFLD) increased during antiviral therapy, and patients with new-onset and sustained NAFLD showed poorer treatment outcomes, including lower rates of biochemical response and fibrosis improvement.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Medicine, General & Internal
Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu
Summary: A noninvasive diagnostic model was constructed to identify patients who need anti-HBV therapies in patients with CBI with concurrent NAFLD, which is important for clinical application.
FRONTIERS IN MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Siyu Zhang, Xiaoxiao Zhang, Huiming Jin, Yao Dou, Lu Li, Xiwei Yuan, Chen Dong, Mengmeng Hou, Yue-Min Nan, Jia Shang
Summary: This study found that in CHB patients receiving antiviral therapy, the presence of NAFLD was associated with higher levels of HBV DNA, pgRNA, and liver enzymes, as well as a higher incidence of LLV and delayed CVR.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2023)
Article
Immunology
Jie Li, Hwai- Yang, Ming-Lun Yeh, Michael H. Le, An K. Le, Yee Hui Yeo, Chia-Yen Dai, Scott Barnett, Jian Q. Zhang, Jee-Fu Huang, Huy N. Trinh, Christopher Wong, Clifford Wong, Joseph K. Hoang, Ramsey Cheung, Ming-Lung Yu, Mindie H. Nguyen
Summary: This study found that concurrent FL in patients with CHB significantly reduces the risk of cirrhosis and HCC, as well as increases the rate of HBsAg seroclearance. Further research is needed to confirm these findings and investigate the underlying mechanisms of FL on CHB.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Oncology
Minah Kim, Yeonju Lee, Jun Sik Yoon, Minjong Lee, So Shin Kye, Sun Woong Kim, Yuri Cho
Summary: In patients with coexisting nonalcoholic fatty liver disease and chronic hepatitis B, a high FIB-4 index (>= 1.77) may be a useful predictor for the development of hepatocellular carcinoma (HCC).
Article
Gastroenterology & Hepatology
Javier Ampuero, Rocio Aller, Rocio Gallego-Duran, Javier Crespo, Javier Abad, Agueda Gonzalez-Rodriguez, Judith Gomez-Camarero, Joan Caballeria, Oreste Lo Iacono, Luis Ibanez, Javier Garcia-Samaniego, Rosa Martin-Mateos, Ruben Frances, Conrado Fernandez-Rodriguez, Moises Diago, German Soriano, Raul J. Andrade, Raquel Latorre, Francisco Jorquera, Rosa M. Morillas, Desam Escudero, Pamela Estevez, Manuel Hernandez-Guerra, Salvador Augustin, Maria Jesus Pareja-Megia, Jesus M. Banales, Patricia Aspichueta, Salvador Benlloch, Jose Miguel Rosales, Javier Salmeron, Juan Turnes, Manuel Romero-Gomez
Summary: The study investigated the distribution of NASH and its components across fibrosis stages, revealing a decrease in steatohepatitis prevalence in advanced liver disease. However, most patients still showed inflammatory activity and metabolic disturbances. The risk of cirrhosis progression was similar between NASH and indeterminate NASH patients.
LIVER INTERNATIONAL
(2021)
Review
Endocrinology & Metabolism
Zhijia Zhou, Jinghao Zhang, Liping You, Tao Wang, Kaixia Wang, Lingtai Wang, Xiaoni Kong, Yueqiu Gao, Xuehua Sun
Summary: Non-alcoholic fatty liver disease (NAFLD) is a global health problem, and traditional Chinese medicine (TCM) has shown potential in its treatment. This article summarizes the research and evidence on the effectiveness of herbal therapy for NAFLD or NASH, and attempts to establish the links between TCM theory and modern pharmacological mechanisms. It provides ideas and perspectives for further exploration of the pathogenesis of NAFLD and herbal therapy, promoting the scientific connotation of TCM theories and the modernization of TCM.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Gastroenterology & Hepatology
Shang -Chin Huang, Chun-Jen Liu
Summary: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. The interactions between fatty liver disease and the hepatitis B virus (HBV) as well as their clinical impacts are complex. The presence of hepatic steatosis may suppress HBV viral activity, while co-morbidities like diabetes mellitus or obesity may increase the risk of adverse liver outcomes. This article reviews the evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming to optimize holistic health care in the CHB population. (Clin Mol Hepatol 2023;29:320-331)
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Mohamed Salaheldin, Heba Aly, Louis Lau, Shimaa Afify, Mohamed El-Kassas
Summary: Over the years, the complications of viral hepatitis and alcohol-related liver diseases have been a major concern in hepatology. However, recent advancements in the field have revealed a paradigm shift towards nonalcoholic fatty liver disease (NAFLD) as the leading cause of liver cirrhosis and cancer. This review focuses on updating knowledge about the pathogenesis of NAFLD-induced hepatocellular carcinoma (HCC), surveillance challenges, and potential disease markers, such as molecular biomarkers, which may revolutionize risk stratification, early detection, and treatment selection for NAFLD-related HCC.
Article
Oncology
Lei Liu, Si Xie, Yu-Xian Teng, Zhu-Jian Deng, Kang Chen, Hao-Tian Liu, Rong-Rui Huo, Xiu-Mei Liang, Ping-Ping Guo, Da-Long Yang, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong
Summary: The study found that patients with HCC in the context of MAFLD had less severe background liver disease at the time of HCC diagnosis and better long-term survival after curative liver resection compared to counterparts with CHB/MAFLD or CHB.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Bou-Zenn Lin, Tsung-Jung Lin, Chih-Lin Lin, Li-Ying Liao, Ting-An Chang, Buo-Jia Lu, Kuan-Yang Chen
Summary: The study found that NAFLD-related HCC patients were older, heavier, and more likely to have diabetes compared to HBV-related patients. Additionally, a higher proportion of NAFLD-related patients were noncirrhotic. Overall survival rates did not significantly differ between NAFLD and HBV-related HCC patients.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Qi Wang, Wen Xie, Ligai Liu, Peng Wang, Calvin Q. Pan
Summary: The study found that in NAFLD patients, the AST to platelet ratio index is the most accurate marker for predicting advanced fibrosis, while in patients without CHB, fibrosis-4 is the best performing marker. Serum markers are less reliable in predicting advanced fibrosis in NAFLD patients with CHB; APRI is the most accurate predictor of the absence of advanced fibrosis.